Blood pressure-lowering and antiproteinuric effect of switching from high-dose angiotensin receptor blockers to normal-dose telmisartan and low-dose hydrochlorothiazide in hypertensive patients with chronic kidney disease

International Journal of Clinical Pharmacology and Therapeutics

Volumn 48, Issue 3, 2010, Pages 206-213

  Abe, M ^a   Okada, K ^a   Maruyama, T ^a   Matsumoto, S ^a   Matsumoto, K ^a  

^a NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Angiotensin receptor blocker; Chronic kidney disease; Hydrochlorothiazide; Telmisartan; Urinary protein excretion

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FUROSEMIDE; HYDROCHLOROTHIAZIDE PLUS TELMISARTAN; LOSARTAN; OLMESARTAN; TELMISARTAN; VALSARTAN;

ADULT; ANEMIA; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE URINE LEVEL; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DISEASE CONTROL; DISEASE SEVERITY; DRUG COST; DRUG EFFICACY; DRUG ERUPTION; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPOKALEMIA; HYPONATREMIA; HYPOTENSION; LIVER DISEASE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PROTEINURIA; PULSE RATE; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; URINARY EXCRETION; URINARY FREQUENCY;

EID: 77949458675     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CPP48206     Document Type: Article

References (24)

1. Abe M, Okada K, Matsumoto K. Clinical experience in treating hypertension with fixed-dose combination therapy: angiotensin II receptor blocker losartan plus hydrochlorothiazide. Expert Opin Drug Metab Toxicol. 2009; 5: 1285-1303.
2. Bakris GL, Toto RD, McCullough PA, Rocha R, Purkayastha D, Davis P; GUARD (Gauging Albuminuria Reduction With Lotrel in Diabetic Patients With Hypertension) Study Investigators. Effects of different ACE inhibitor combinations on albuminuria: results of the GUARD study. Kidney Int. 2008; 73: 1303-1309.
3. Brenner BM, Cooper MD, De Zeeuw D et al. RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Eng J Med. 2001; 345: 861-869.
4. Carlsen JE, Kober L, Torp-Pedersen C, Johansen P. Relation between dose of bendrofluazide, antihypertensive effect, and adverse biochemical effects. BMJ. 1990; 300: 975-978.
5. Chobanian AV, Bakris GL, Black HR et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003; 289: 2560-2572.
6. Dzau VJ. Theodore Cooper Lecture: tissue angiotesin and pathobiology of vascular disease: a unifying hypothesis. Hypertension. 2001; 37: 1047-1052.
7. Gaede P, Tarnow L, Vedel P, Parving HH, Pedersen O. Remission to normoalbuminuria during multifactorial treatment preserves kidney function in patients with type 2 diabetes and microalbuminuria. Nephrol Dial Transplant. 2004; 19: 2784-2788.
8. Jafar TH, Stark PC, Schmid CH, Landa M, Maschio G, Marcantoni C, Jong PED, Zeeuw DD, Shahinfar S, Ruggenenti P, Remuzzi G, Levey AS. Proteinuria as a modifiable risk factor for the progression of nondiabetic renal disease. Kidney Int. 2001; 60: 1131-1140.
9. Japanese Society of Hypertension. Japanese Society of Hypertension Guidelines for Management of Hypertension (JSH 2009). Hypertens Res. 2009; 32: 3-107.
10. Jounela AJ, Lilja M, Lumme J et al. Relation between low dose of hydrochlorothiazide, antihypertensive effect and adverse effects. Blood Press. 1994; 3: 231-235.
11. KDOQI. KDOQI clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease. AmJ Kidney Dis. 2007; 49: 12-154.
12. Lavermann GD, Henning RH, De Jong PE, Navis G, Zeeuw D. Optimal antiproteinuric dose of losartan in nondiabetic patients with nephrotic range proteinuria. Am J Kidney Dis. 2001; 38: 1381-1384.
13. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Eng J Med. 1993; 329: 1456-1462.
14. Marcantoni C, Jafar TH, Oldrizzi L, Levey AS, Mascio G. The role of systemic hypertension in the progression of nondiabetic renal disease. Kidney Int. 2000; 57 (Suppl): 44-48.
15. Matsuo S, Imai E, Horio M et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009; 53: 982-992.
16. Nakashima M, Uematsu T, Kosuge K, Kanamaru M. Pilot study of the uricosuric effect of DuP-753, a new angiotensin II receptor antagonist, in healthy subjects. Eur J Clin Pharmacol. 1992; 42: 333-335.
17. Nakayama S, Watada H, Mita T et al. Comparison of effects of olmesartan and telmisartan on blood pressure and metabolic parameters in Japanese early-stage Type-2 diabetics with hypertension. Hypertens Res. 2008; 31: 7-13.
18. Parving HH, Andersen AR, Smidt UM, Svendsen PA. Early aggressive antihypertensive treatment reduces rate of decline in kidney function in diabetic nephropathy. Lancet. 1983; 1: 1175-1179.
19. Plavinik FL, Rodrigues CL, Zanella MT, Ribeiro AB. Hypokalemia, glucose intolerance, and hyperinsulinemia during diuretic therapy. Hypertension. 1992; 19: 26-29.
20. Rossing K, Christensen PK, Hovind P, Parving HH. Remission of nephrotic-range albuminuria reduces risk of end-stage renal disease and improves survival in Type 2 diabetic patients. Diabetologia. 2005; 11: 2241-2247.
21. Sheinfield GR, Bakris GL. Benefits of combination angiotensin-converting enzyme inhibitor and calcium antagonist therapy for diabetic patients.AmJ Hypertens. 1999; 12: 80-85.
22. Shimosawa T, Gohchi K, Yatomi Y, Fujita T. Effectiveness of add-on low dose diuretics in combination therapy for hypertension: losartan/hydrochlorothiazide vs. candesartan/amlodipine. Hypertens Res. 2007; 30: 831-837.
23. Waeber B. Managing hypertension in high-risk patients: lessons and promises from the STRATHE and ADVANCE trials. J Hypertens. 2006; 24: 19-27.
24. Zhang C, Hein TW, Wang W, Kuo L. Divergent roles of angiotensin II AT1 and AT2 receptors in modulating coronary microvascular function. Circ Res. 2003; 92: 322-329.